{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:51:49Z","timestamp":1793681509155,"version":"4.5.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>KRd has a favorable benefit-risk profile compared with Rd, regardless of baseline cytogenetic risk status, in patients with relapsed MM. KRd improves but does not abrogate the poor prognosis associated with high-risk cytogenetics in patients with relapsed MM.<\/jats:p>","DOI":"10.1182\/blood-2016-03-707596","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T03:28:55Z","timestamp":1469071735000},"page":"1174-1180","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":109,"title":["Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma"],"prefix":"10.1182","volume":"128","author":[{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"first","affiliation":[{"name":"Centre de Recherche en Canc\u00e9rologie de Toulouse INSERM U1037, Toulouse, France;"},{"name":"L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Praha, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"St. Istv\u00e1n and St. Laszlo Hospital, Budapest, Hungary;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesselina","family":"Goranova-Marinova","sequence":"additional","affiliation":[{"name":"Hematology Clinic University Multiprofile Hospital for Active Treatment \u201cSv. Georgi\u201d and Medical University, Plovdiv, Bulgaria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Mihaylov","sequence":"additional","affiliation":[{"name":"Queen Joanna University Hospital, Sofia, Bulgaria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Maisnar","sequence":"additional","affiliation":[{"name":"Charles University Faculty Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca\/Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"University of Torino, Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ben-Yehuda","sequence":"additional","affiliation":[{"name":"Hadassah-Hebrew University Medical Center, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Obreja","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals Inc., South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111902331417100_B1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"issue":"2","key":"2019111902331417100_B2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111902331417100_B3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2014.117077","article-title":"Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.","volume":"100","author":"Dimopoulos","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"2019111902331417100_B4","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome.","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2019111902331417100_B5","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du my\u00e9lome experience.","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111902331417100_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.730.730","article-title":"Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the FIRST (MM-020) trial [abstract].","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111902331417100_B7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/leu.2009.273","article-title":"Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.","volume":"24","author":"Avet-Loiseau","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019111902331417100_B8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153].","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"2019111902331417100_B9","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/leu.2013.152","article-title":"Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.","volume":"27","author":"Jakubowiak","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2019111902331417100_B10","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.25775","article-title":"Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.","volume":"117","author":"Klein","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"2019111902331417100_B11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.leukres.2006.08.002","article-title":"Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed\/refractory multiple myeloma.","volume":"31","author":"Chang","year":"2007","journal-title":"Leuk Res"},{"issue":"30","key":"2019111902331417100_B12","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9758","key":"2019111902331417100_B13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"2019111902331417100_B14","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2019111902331417100_B15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma.","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111902331417100_B16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.21273","article-title":"Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient.","volume":"90","author":"Landgren","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"24","key":"2019111902331417100_B17","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111902331417100_B18","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results.","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111902331417100_B19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma.","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111902331417100_B20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111902331417100_B21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111902331417100_B22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma.","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/9\/1174\/1398897\/1174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/9\/1174\/1398897\/1174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:35:41Z","timestamp":1574148941000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/9\/1174\/35776\/Carfilzomib-significantly-improves-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-707596","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}